Top

Published in:

01-10-2007 | Leading Article

The Role of Anti-Inflammatory Agents in Parkinson’s Disease

Authors: Dr Edith G. McGeer, Patrick L. McGeer

Published in: CNS Drugs | Issue 10/2007

Abstract

There is ample and increasing evidence, from studies of human pathology, animal models and tissue culture, that chronic inflammation occurs in the basal ganglia in patients with Parkinson’s disease. In such inflammatory states, activated glia can produce large quantities of free radicals and other neurotoxic materials. Dopaminergic neurons appear to be particularly vulnerable to these neurotoxins.

The anti-inflammatory drugs that are presently in wide use act on peripheral players in the inflammatory process. Many experiments are under way to find agents that inhibit more potent contributors, such as the activated microglia or terminal complement proteins. Whether such drugs will slow the process of Parkinson’s disease or reduce the high risk of dementia in such patients remains to be determined in future work.

Douglas MR, Lewthwaite AJ, Nicholl DJ. Genetics of Parkinson’s disease and parkinsonism. Expert Rev Neurother 2007; 7(6): 657–66PubMedCrossRef

Casarejos MJ, Menendez J, Solano RM, et al. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J Neurochem 2006; 97: 934–46PubMedCrossRef

Hattori N, Machida Y, Sato S, et al. Molecular mechanisms of nigral neurodegeneration in Park2 and regulation of parkin protein by other proteins. J Neural Transmiss Suppl 2006; 70: 205–8CrossRef

Sun M, Latourelle JC, Wooten GF, et al. Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol 2006; 63: 826–32PubMedCrossRef

Smith WW, Pei Z, Jiang H, et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A 2005; 102: 18676–81PubMedCrossRef

West AB, Moore DJ, Biskup S, et al. Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 2005; 102: 16842–7PubMedCrossRef

Kachergus J, Mata IF, Hulihan M, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005; 76: 672–80PubMedCrossRef

Whaley NR, Uitti RJ, Dickson DW, et al. Clinical and pathologic features of families with LRRK2-associated Parkinson’s disease. J Neural Transmiss Suppl 2006; 70: 221–9CrossRef

Ishihara L, Warren L, Gibson R, et al. Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2023S mutations. Arch Neurol 2006; 63: 1250–4PubMedCrossRef

10.

Kay DM, Zabetian CP, Factor SA, et al. Parkinson’s disease and RRK2: frequency of a common mutation in US movement disorder clinics. Movement Dis 2006; 21: 519–23PubMedCrossRef

11.

Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44: 601–7PubMedCrossRef

12.

Davidzon G, Greene P, Mancuso M, et al. Early-onset familial parkinsonism due to POLG mutations. Ann Neurol 2006; 59: 859–62PubMedCrossRef

13.

Skovronsky DM, Lee VMY, Trojanowski JQ. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol Mech Dis 2006; 1: 151–70CrossRef

14.

Miklossy J, Arai T, Guo J-P, et al. LRRK2 expression in normal and pathologic human brain and in human cell lines. J Neuropath Exp Neurol 2006; 65: 953–63PubMedCrossRef

15.

Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130–3PubMedCrossRef

16.

McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 2007; 28(5): 639–47PubMedCrossRef

17.

McGeer PL, Sibley J. Sparing of age-related macular degeneration in rheumatoid arthritis. Neurobiol Aging 2006; 37: 1533–4CrossRef

18.

Kurkowska-Jastrzebska I, Wroska A, Kohutnicka M, et al. MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson’s disease. Acta Neurobiol Exp 1999; 59: 1–8

19.

Kurkowska-Jastrzebska I, Wroska A, Kohutnicka M, et al. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 1999; 156: 50–61PubMedCrossRef

20.

McGeer PL, Itagaki S, Akiyama H, et al. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 1988; 24: 574–6PubMedCrossRef

21.

Miklossy J, Doudet DD, Schwab C, et al. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp Neurol 2006; 197: 275–83PubMedCrossRef

22.

Le WD, Rowe DB, Xie W. Activated microglia induce dopaminergic cell injury in vitro. XIII International Congress on Parkinson’s Disease, Parkinsonism, and Related Disorders; 1999 Jul 24–28; Vancouver (BC). 5(2): S19

23.

Gao HM, Hong JS, Zhang W, et al. Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson’s disease. J Neurosci 2003; 23: 1228–36PubMed

24.

Chung ES, Joe EH, Ryu JK, et al. GT1b ganglioside induces death of dopaminergic neurons in rat mesencephalic cultures. Neuroreport 2001; 12: 611–4PubMedCrossRef

25.

Gao HM, Hong JS, Zhang W, et al. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 2002; 22: 782–90PubMed

26.

He Y, Le WD, Appel SH. Role of Fcgamma receptors in nigral cell injury induced by Parkinson disease immunoglobulin injection into mouse substantia nigra. Exp Neurol 2002; 176: 322–7PubMedCrossRef

27.

Yamada T, McGeer PL, McGeer EG. Relationship of complement-activated oligodendrocytes to reactive microglia and neuronal pathology in neurodegenerative disease. Dementia 1991; 2: 71–7

28.

McGeer PL, Itagaki S, Boyes BE, et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 1988; 38: 1285–91PubMedCrossRef

29.

Orr CF, Rowe DB, Mizuno Y, et al. A possible role for humoral immunity in the pathogenesis of Parkinson’s disease. Brain 2005; 128: 2665–74PubMedCrossRef

30.

Sawada M, Imamura K, Nagatsu T. Role of cytokines in inflammatory process in Parkinson’s disease. J Neural Transmiss Suppl 2006; 70: 373–81CrossRef

31.

Yamada T, McGeer EG, Schelper RL, et al. Histological and biochemical pathology in a family with autosomal dominant Parkinsonism and dementia. Neurol Psychiatry Brain Res 1993; 2: 26–35

32.

Langsten JW, Forno LS, Tetrud J, et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999; 46: 598–605CrossRef

33.

McGeer PL, Schwab C, Parent A, et al. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine administration. Ann Neurol 2003; 54: 599–604PubMedCrossRef

34.

McGeer PL, Yasojima K, McGeer EG. Inflammation in Parkinson’s disease. Adv Neurol 2001; 86: 83–9PubMed

35.

Jenner P. Oxidative stress in Parkinson’s disease. Ann Neurol 2003; 53Suppl. 3: S26–36PubMedCrossRef

36.

Koutsilieri E, Scheller C, Grunblatt E, et al. Free radicals in Parkinson’s disease. J Neurol 2002; 249Suppl. 2: II1–5PubMed

37.

Gerhard A, Pavese N, Hotten G, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 2006; 21: 404–12PubMedCrossRef

38.

Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 2005; 57: 168–75PubMedCrossRef

39.

Cicchetti F, Brownell AL, Williams K, et al. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 2002; 15: 991–8PubMedCrossRef

40.

Sugama S, Yang L, Cho BP, et al. Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/ 6 mice. Brain Res 2003; 964: 288–94PubMedCrossRef

41.

Gao HM, Liu B, Hong JS. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 2003; 23: 6181–7PubMed

42.

Sherer TB, Betarbet R, Kim JH, et al. Selective microglial activation in the rat rotenone model of Parkinson’s disease. Neurosci Lett 2003; 341: 87–90PubMedCrossRef

43.

Douhou A, Debeir T, Michel PP, et al. Differential activation of astrocytes and microglia during post-natal development of dopaminergic neuronal death in the weaver mouse. Dev Brain Res 2003; 145: 9–17CrossRef

44.

Arimoto T, Bing G. Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol Dis 2003; 12: 35–45PubMedCrossRef

45.

Iravani MM, Kashefi K, Mander P, et al. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 2002; 110: 49–58PubMedCrossRef

46.

Ryu JK, Shin WH, Kim J, et al. Trisialoganglioside GT1b induces in vivo degeneration of nigral dopaminergic neurons: role of microglia. Glia 2002; 38: 15–23PubMedCrossRef

47.

McLaughlin P, Zhou Y, Ma T, et al. Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity. Glia 2006; 53: 567–82PubMedCrossRef

48.

Shavali S, Combs CK, Ebadi M. Reactive macrophages increase oxidative stress and alpha-synuclein nitration during death of dopaminergic neuronal cells in co-culture: relevance to Parkinson’s disease. Neurochem Res 2006; 31: 85–94PubMedCrossRef

49.

Walker DG, Lue L-F, Klegeris A, et al. The involvement of glial cell-derived reactive oxygen and nitrogen species in Alzheimer’s disease. In: Rogers J, editor. Neuroinflammatory mechanisms in Alzheimer’s disease: basic and clinical research. Basel: Birkhauser Verlag, 2001: 173–95CrossRef

50.

Herrera AJ, Castano A, Venero JL, et al. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on the dopaminergic system. Neurobiol Dis 2000; 7: 429–47PubMedCrossRef

51.

Gao HM, Jiang J, Wilson B, et al. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson’s disease. J Neurochem 2002; 81: 1285–97PubMedCrossRef

52.

Kim WG, Mohney RP, Wilson B, et al. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 2000; 20: 6309–16PubMed

53.

Zhang W, Wang T, Pei Z, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB J 2005; 19: 533–42PubMedCrossRef

54.

Ciesielski-Treska J, Ulrich G, Taupenot L, et al. Chromogranin A induces a neurotoxic phenotype in brain microglial cells. J Biol Chem 1998; 273: 14339–46PubMedCrossRef

55.

Yasuhara O, Kawamata T, Aimi Y, et al. Expression of chromogranin A in lesions of the central nervous system from patients with neurological diseases. Neurosci Lett 1994; 170: 13–6PubMedCrossRef

56.

Lee DY, Oh YJ, Jin BK. Thrombin-activated microglia contribute to death of dopaminergic neurons in rat mesencephalic cultures: dual roles of mitogen-activated protein kinase signaling pathways. Glia 2005; 51: 98–110PubMedCrossRef

57.

Ishida Y, Nagai A, Kobayashi S, et al. Upregulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase. J Neuropath Exp Neurol 2006; 65: 66–77PubMedCrossRef

58.

Wilms H, Rosenstiel P, Sievers J, et al. Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson’s disease. FASEB J 2003; 17: 500–2PubMed

59.

Aimi Y, McGeer PL. Lack of toxicity of human neuromelanin to rat brain dopaminergic neurons. Parkinsonism Relat Disord 1996; 2: 69–74PubMedCrossRef

60.

Mosser DM. The many faces of macrophage activation. J Leuko Biol 2003; 73: 209–12PubMedCrossRef

61.

Mogi M, Harada M, Riederer P, et al. Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 1994; 165: 208–10PubMedCrossRef

62.

Boka G, Anglade P, Wallach D, et al. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson’s disease. Neurosci Lett 1994; 172: 151–4PubMedCrossRef

63.

Hunot S, Dugas N, Faucheux B, et al. Fc epsilon RII/CD23 is expressed in Parkinson’s disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci 1999; 19: 3440–7PubMed

64.

McGeer PL, Yasojima K, McGeer EG. Association of interleukin-1 beta polymorphisms with idiopathic Parkinson’s disease. Neurosci Lett 2002; 326: 67–9PubMedCrossRef

65.

Schulte T, Schols L, Muller T, et al. Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson’s disease. Neurosci Lett 2002; 326: 70–2PubMedCrossRef

66.

Hakansson A, Westberg L, Nilsson S, et al. Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor beta on the susceptibility to Parkinson’s disease. Am J Med Genetics 2005; 133: 88–92

67.

Hakansson A, Westberg L, Nilsson S, et al. Investigation of genes coding for inflammatory components in Parkinson’s disease. Movement Dis 2005; 20: 569–73PubMedCrossRef

68.

Gayle DA, Ling ZD, Tong CW, et al. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-α, interleukin-1b, and nitric oxide. Dev Brain Res 2002; 133: 27–36CrossRef

69.

Sriram K, Matheson JM, Benkovic SA, et al. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson’s disease. FASEB J 2002; 16: 1474–6PubMed

70.

Henze C, Hartmann A, Lescot T, et al. Proliferation of microglial cells induced by 1-methyl-4-phenylpyridinium in mesencephalic cultures results from an astrocyte-dependent mechanism: role of granulocyte macrophage colony-stimulating factor. J Neurochem 2005; 95: 1069–77PubMedCrossRef

71.

Yamada T, McGeer PL, McGeer EG. Lewy bodies in Parkinson’s disease are recognized by antibodies to complement proteins. Acta Neuropathol 1992; 84: 100–4PubMedCrossRef

72.

Goldknopf IL, Sheta EA, Bryson J, et al. Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson’s disease. Biochem Biophys Res Commun 2006; 342: 1034–9PubMedCrossRef

73.

Chen H, Zhang SM, Herman MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003; 60: 1059–64PubMedCrossRef

74.

Chen H, Jacobs E, Schwarzschild MA, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson’s disease. Ann Neurol 2005; 58: 963–7PubMedCrossRef

75.

Bower JH, Maraganore DM, Peterson BJ, et al. Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study. Neurology 2006; 67: 494–6PubMedCrossRef

76.

Hernan MA, Logroscino G, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 2006; 66: 1097–9PubMedCrossRef

77.

Peng J, Xie L, Stevenson FF, et al. Nigrostriatal dopaminergic neurodegeneration in the weaver mouse is mediated via neuroinflammation and alleviated by minocycline administration. J Neurosci 2006; 6: 11644–51CrossRef

78.

Du Y, Ma Z, Lin S, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease. Proc Natl Acad Sci U S A 2001; 98: 14669–74PubMedCrossRef

79.

Wu DC, Jackson-Lewis V, Vila M, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. J Neurosci 2002; 22: 1763–71PubMed

80.

He Y, Appel S, Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 2001; 909: 187–93PubMedCrossRef

81.

Wang T, Zhang W, Pei Z, et al. Reactive microgliosis participates in MPP+-induced dopaminergic neurodegeneration: role of 67 kDa laminin receptor. FASEB J 2006; 20: 906–15PubMedCrossRef

82.

Li G, Cui G, Tzeng NS, et al. Femtomolar concentrations ofdextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage. FASEB J 2005; 19: 489–96PubMedCrossRef

83.

Noelker C, Bacher M, Gocke P, et al. The flavanoide caffeic acid phenethyl ester blocks 6-hydroxydopamine-induced neurotoxicity. Neurosci Lett 2005; 383: 39–43PubMedCrossRef

84.

Lastres-Becker I, Molina-Holgado F, Ramos JA, et al. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease. Neurobiol Dis 2005; 19: 96–107PubMedCrossRef

85.

Fahrig T, Gerlach I, Horvath E. A synthetic derivative of the natural product rocaglaol is a potent inhibitor of cytokine-mediated signaling and shows neuroprotective activity in vitro and in animal models of Parkinson’s disease and traumatic brain injury. Mol Pharmacol 2005; 67: 1544–55PubMedCrossRef

86.

Zhang W, Qin L, Wang T, et al. 3-Hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity. FASEB J 2005; 19: 395–7PubMed

87.

McCoy MK, Martinez TN, Ruhn KA, et al. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson’s disease. J Neurosci 2006; 26: 9365–75PubMedCrossRef

88.

Zoccarato F, Toscano P, Alexandre A. Dopamine-derived dopaminochrome promotes H(2)O(2) release at mitochondrial complex I: stimulation by rotenone, control by Ca(2+), and relevance to Parkinson disease. J Biol Chem 2005; 280: 15587–94PubMedCrossRef

89.

Choi DK, Pennathur S, Perier C, et al. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson’s disease in mice. J Neurosci 2005; 25: 6594–600PubMedCrossRef

90.

Cardona AE, Pioro EP, Sasse ME, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nature Neurosci 2006; 9: 917–24PubMedCrossRef

Title: The Role of Anti-Inflammatory Agents in Parkinson’s Disease
Authors: Dr Edith G. McGeer
Patrick L. McGeer
Publication date: 01-10-2007
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 10/2007
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200721100-00001

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Role of Anti-Inflammatory Agents in Parkinson’s Disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2007

Hashimoto’s Encephalopathy

Mechanisms Underlying Postoperative Nausea and Vomiting and Neurotransmitter Receptor Antagonist-Based Pharmacotherapy

Biological Treatments for Amfetamine Dependence

Ziprasidone for the Treatment of Acute Manic or Mixed Episodes Associated with Bipolar Disorder

Subcutaneous Interferon-β-1a